273 related articles for article (PubMed ID: 20504137)
1. The Food and Drug Administration risk evaluation and mitigation strategy.
Craig DS
J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
[TBL] [Abstract][Full Text] [Related]
2. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
Stanos S
Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
[TBL] [Abstract][Full Text] [Related]
3. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
[TBL] [Abstract][Full Text] [Related]
4. The Food and Drug Administration opioid Risk Evaluation and Mitigation Strategy.
Lipman AG
J Pain Palliat Care Pharmacother; 2009; 23(3):219-21. PubMed ID: 19670017
[No Abstract] [Full Text] [Related]
5. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
Gudin J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):136-43. PubMed ID: 22764852
[TBL] [Abstract][Full Text] [Related]
6. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
Sloan PA
J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
[No Abstract] [Full Text] [Related]
7. Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.
Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):123-6. PubMed ID: 22764848
[TBL] [Abstract][Full Text] [Related]
8. Examination of risk evaluation and mitigation strategies and drug safety in the US.
Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
[TBL] [Abstract][Full Text] [Related]
9. Understanding risk evaluation and mitigation strategies in organ transplantation.
Gabardi S
Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
[TBL] [Abstract][Full Text] [Related]
10. Blueprint for prescriber continuing education program.
Center For Drug Evaluation And Research Food And Drug Administration
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):127-30. PubMed ID: 22764849
[TBL] [Abstract][Full Text] [Related]
11. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
Peppin JF; Coleman JJ; Kirsh KL
Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
[TBL] [Abstract][Full Text] [Related]
12. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context.
Leiderman DB
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069
[TBL] [Abstract][Full Text] [Related]
13. Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?
Brooks MJ
Mayo Clin Proc; 2014 Dec; 89(12):1673-84. PubMed ID: 25441401
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
Nicholson S; Peterson J; Yektashenas B
Expert Opin Drug Saf; 2012 Mar; 11(2):299-314. PubMed ID: 22233294
[TBL] [Abstract][Full Text] [Related]
15. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
Matthews ML
J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
[TBL] [Abstract][Full Text] [Related]
16. FDA acts to reduce harm from opioid drugs.
J Pain Palliat Care Pharmacother; 2011; 25(3):296-7. PubMed ID: 21882983
[No Abstract] [Full Text] [Related]
17. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
Meyer BM
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
[TBL] [Abstract][Full Text] [Related]
18. [Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine].
Li Y; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2825-7. PubMed ID: 22292376
[TBL] [Abstract][Full Text] [Related]
19. Has the FDA Amendments Act of 2007 impaired drug development?
Franson TR
Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
[TBL] [Abstract][Full Text] [Related]
20. Risk evaluation mitigation strategies: the evolution of risk management policy.
Hollingsworth K; Toscani M
Popul Health Manag; 2013 Apr; 16(2):132-7. PubMed ID: 23113627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
